Zobrazeno 1 - 10
of 246
pro vyhledávání: '"Mark A Wainberg"'
Autor:
Bluma G. Brenner, Mark A. Wainberg, Thibault Mesplède, Nathan Osman, Maureen Oliveira, Said Hassounah
Publikováno v:
AIDS. 32:1773-1780
Objectives Dolutegravir (DTG) has achieved better long-term suppression of HIV-1 replication than other integrase strand transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir (EVG). In in-vitro drug washout experiments, we previous
Autor:
Vladimir Novitsky, Simani Gaseitsiwe, Max Essex, Joseph Makhema, Richard Marlink, Harriet Okatch, Sikhulile Moyo, Thabo Diphoko, Ishmael Kasvosve, Mark A. Wainberg, Rosemary Musonda
Publikováno v:
AIDS Research and Human Retroviruses. 34:667-671
Rilpivirine (RPV) and Etravirine (ETR) are approved second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV treatment. There is a cross-resistance HIV mutation profile between first- and second-generation NNRTI drugs. We de
Autor:
Lothar Resch, Michael Gill, Glen B. Baker, Wing Fuk Chan, Oussama Meziane, Christopher Power, Éric A. Cohen, Eugene L. Asahchop, William G. Branton, Mark A. Wainberg, Manmeet K. Mamik, Jean V. Guimond, Elie Haddad
Publikováno v:
Retrovirology, Vol 14, Iss 1, Pp 1-17 (2017)
Retrovirology
Retrovirology
Background In patients with HIV/AIDS receiving antiretroviral therapy (ART), HIV-1 persistence in brain tissue is a vital and unanswered question. HIV-1 infects and replicates in resident microglia and trafficking macrophages within the brain althoug
Autor:
Julie Bruneau, Colin Kovacs, Jean-Pierre Routy, Alexandra Tremblay-McLean, Irene Lisovsky, Mark A. Wainberg, Gamze Isitman, Cécile Tremblay, Nicole F. Bernard, Marianne Harris
Publikováno v:
AIDS Research and Human Retroviruses. 32:1079-1088
Carriage of alleles encoding certain inhibitory natural killer (NK) cell receptor/HLA ligand KIR3DL1/HLA-B combinations is associated with protection from HIV infection and slow time to AIDS, implicating NK cells in HIV control. NK cells also mediate
Autor:
Ruxandra I. Ibanescu, Bluma G. Brenner, Mark A. Wainberg, Thibault Mesplède, Maureen Oliveira, Hanh T. Pham
Publikováno v:
AIDS. 30:2267-2273
Objective Recommended treatments for newly diagnosed HIV-positive individuals now focus on the integrase strand transfer inhibitors, raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). In treatment-naive individuals, cases of RAL-based and
Autor:
Laurence Meyer, Julie Chas, Jean-Guy Baril, Véronique Doré, Michel Morin, Jean-Pierre Aboulker, Marine Saouzanet, Isabelle Durant-Zaleski, Marie Suzan-Monti, Emmanuelle Netzer, Françoise Euphrasie, Nathalie Bajos, Séverine Gibowski, Soizic Le Mestre, Gilles Peytavin, Jean-François Delfraissy, Constance Delaugerre, David Thompson, Brigitte Guillon, Gilles Pialoux, Alpha Diallo, Nicolas Etien, Christian Chidiac, Michel Besnier, Isabelle Charreau, Benoit Trottier, Baptiste Demoulin, Julie Timsit, Bruno Spire, Joanne Otis, Laurent Cotte, Julien Fonsart, W. Rozenbaum, Mark A. Wainberg, Gabriel Girard, Eric Cua, Guillemette Antoni, Daniela Rojas Castro, Catherine Capitant, Luis Sagaon-Teyssier, Antoine Cheret, Marie-Christine Simon, Cécile Tremblay, Nicolas Leturque, Johan Binesse, Diane Carette, Valérie Foubert, Anaïs Mennecier, Grégoire Cattin, Jean-Michel Molina, Yacine Saïdi, Nicolas Lorente, Elias Choucair, François Raffi, Cecile Rabian, Armelle Pasquet, Marie Préau, Thomas Huleux
Publikováno v:
The Lancet HIV
The Lancet HIV, 2020, 7 (2), pp.e113-e120. ⟨10.1016/S2352-3018(19)30341-8⟩
The Lancet HIV, 2020, 7 (2), pp.e113-e120. ⟨10.1016/S2352-3018(19)30341-8⟩
Summary Background ANRS IPERGAY found that on-demand pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus emtricitabine was associated with an 86% relative reduction of HIV-1 incidence compared with placebo among men who have
Publikováno v:
Pathogens and Immunity, Vol 1, Iss 1, Pp 41-67 (2016)
Pathogens & Immunity
Pathogens & Immunity
Since the discovery of the first inhibitors of HIV replication, drug resistance has been a major problem in HIV therapy, due, in part, to the high mutation rate of HIV. Therefore, the development of a predictive animal model is important to identify
Publikováno v:
Journal of Virology. 92
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals to be approved for the treatment of HIV infection. Canonical resistance to these competitive inhibitors develops through substitutions in the integrase active site
Autor:
Daniela Moisi, Peter K. Quashie, Mark A. Wainberg, Thibault Mesplède, Yannan Liu, Maureen Oliveira, Said Hassounah, Bluma G. Brenner, Paul Sandstrom
Publikováno v:
Journal of Virology. 89:12002-12013
We previously showed that the simian immunodeficiency virus SIVmac239 is susceptible to human immunodeficiency virus (HIV) integrase (IN) strand transfer inhibitors (INSTIs) and that the same IN drug resistance mutations result in similar phenotypes
Autor:
Daniela Moisi, Bluma G. Brenner, Ruxandra-Ilinca Ibanescu, Thibault Mesplède, Mark A. Wainberg, Maureen Oliveira
Publikováno v:
AIDS. 29:2255-2260
Objective Although the integrase inhibitor dolutegravir (DTG) has demonstrated greater resilience than other antiretroviral drugs at withstanding the emergence of HIV-1 resistance mutations, such substitutions can develop, albeit rarely, in treatment